A nomogram integrating DCE-MRI imaging features and clinicopathological parameters for predicting pathological complete response in HER2-positive breast cancer
Frontiers in Oncology · 24.06.2026 · 16
DOI: 10.3389/fonc.2026.1827442 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 24.06.2026. Verfasst von Jianlong Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Oncology, Center for Cancer Prevention and Treatment, Meizhou People's Hospital (Huangtang Hospital), Meizhou Academy of Medical…. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
HER2-positive breast cancer represents approximately 15-20% of all breast cancers and is characterized by aggressive biological behavior. Neoadjuvant chemotherapy (NAC) has become standard treatment, with pathological complete response (pCR) serving as a crucial prognostic indicator. This study aimed to develop and validate a nomogram integrating dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) features and clinicopathological parameters for predicting pCR in HER2-positive breast cancer patients receiving NAC.
Methods
We retrospectively analyzed 183 HER2-positive breast cancer patients who received NAC followed by surgery between January 2015 and December 2024. After excluding 17 patients with incomplete data, 166 patients were randomly divided into training (n=111) and validation (n=55) cohorts. DCE-MRI imaging features including tumor size, lymph node status, apparent diffusion coefficient (ADC) values, and tumor location parameters were extracted. Clinicopathological variables including age, BMI, hormone receptor status, Ki-67 index, clinical staging, and treatment regimen were analyzed. Molecular characterization and multi-omics feature analysis were performed to identify independent predictors of pCR. A nomogram was constructed and validated using receiver operating characteristic (ROC) curves, calibration plots, and decision curve analysis (DCA).
Results
The overall pCR rate was 44.6% (74/166 evaluable patients). Molecular subtype analysis revealed significantly higher pCR rates in HR-/HER2+ patients (52.2%) versus HR+/HER2+ patients (38.5%, P = 0.048). Gene set enrichment analysis identified HER2 signaling and cell proliferation pathways as the most significantly enriched pathways in pCR responders. Multi-omics feature integration identified ADCmin value, Ki-67 index, tumor size, clinical N stage, and HR status as independent predictors. The nomogram demonstrated excellent discrimination with AUC of 0.823 (95%CI: 0.754-0.892) in the training cohort and 0.795 (95%CI: 0.691-0.899) in the validation cohort. Calibration plots showed good agreement (Hosmer-Lemeshow P = 0.412). DCA confirmed clinical utility across threshold probabilities of 0.15-0.75.
Conclusions
We successfully developed and validated a nomogram integrating DCE-MRI features and clinicopathological parameters for predicting pCR in HER2-positive breast cancer. This practical tool may facilitate individualized treatment decision-making.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Breast Oncology, Center for Cancer Prevention and Treatment, Meizhou People's Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences, Meizhou, Guangdong, China.
- Radiotherapy Center, Center for Cancer Prevention and Treatment, Meizhou People's Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences, Meizhou, Guangdong, China.
Zitieren
APA
Wu, J., Gao, B., Wu, J., Peng, Z., Ye, M., Zhong, C., Zhuang, M., & Zhang, J. (2026). A nomogram integrating DCE-MRI imaging features and clinicopathological parameters for predicting pathological complete response in HER2-positive breast cancer. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1827442
Vancouver
Wu J, Gao B, Wu J, Peng Z, Ye M, Zhong C, et al. A nomogram integrating DCE-MRI imaging features and clinicopathological parameters for predicting pathological complete response in HER2-positive breast cancer. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1827442
BibTeX
@article{Wu2026,
author = {Wu, Jianlong and Gao, Bo and Wu, Jingna and Peng, Zhongsheng and Ye, Min and Zhong, Changyou and Zhuang, Mengxia and Zhang, Jinfeng},
title = {A nomogram integrating DCE-MRI imaging features and clinicopathological parameters for predicting pathological complete response in HER2-positive breast cancer},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1827442}
}
EUVIMED